Wall Street's M&A Chatter From June 12: Neuroderm, Penn Virginia, Tesaro, Synaptics-Conexant

The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday, June 12, 2017.

Sanofi, Gilead Said to Consider $10B Deal for Tesaro

The Rumor:

Shares of TESARO Inc TSRO spiked sharply higher Monday on a report that both Sanofi SA (ADR) SNY and Gilead Sciences, Inc. GILD could bid $10 billion for the biotech company, according to Street Insider. Shares traded as high as $141.71 on the report.

The Wall Street Journal reported earlier this month that Tesaro is planning a sale of the company.

Tesaro closed at $142.67, up $3.89.

Neuroderm Said to be Considering Sale

The Rumor:

Share of Neuroderm Ltd NDRM spiked to a high of $24.95 as Bloomberg reported the company is considering a sale. Neuroderm has three clinical stage product candidates for various stages of Parkinson’s disease.

Neuroderm closed at $25.00, up $3.25.

Penn Virginia Exploring Sale

The Rumor:

Penn Virginia Corporation PVAC has hired Jefferies to help it explore a potential sale, according to sources as reported by Reuters. A potential sale is among the strategic alternatives being considered.

Penn Virginia emerged from bankruptcy last September.

Penn Virginia closed at $42.66, down $0.91.

Synaptics to Acquire Conexant for $300M in Cash

The Deal:

Synaptics, Incorporated SYNA reported in an 8-K filing that on June 11, 2017, the Company entered into a securities purchase agreement to acquire all of the outstanding limited liability company interests of Conexant for $300 million in cash 726,666 shares of Synaptics common stock, to be issued at closing in an exempt private placement. The acquisition is expected to close in Q1 of fiscal year 2018.

The purchase agreement is subject to termination if the transaction is not completed on or before December 8, 2017.

Synaptics closed at $58.79, down $0.87.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsRumorsM&A
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...